Aciphex

(rabeprazole)

ApprovedSmall molecule

Rabeprazole is used to treat acid reflux disease, heartburn, and stomach ulcers by reducing the amount of acid your stomach produces.[2] Aciphex is currently approved and in use across 19 indications[4].[1]

Aciphex is one of 258 small molecule programs targeting Gastrointestinal hemorrhage. It is currently in Approved.

Indications

100

Total Trials

Active Trials

257

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Gastrointestinal HemorrhageApproved

Helicobacter Pylori Infectious DiseaseApproved

Lymphoid NeoplasmApproved

Gastric UlcerActive, not recruiting

Bacterial DiseaseActive, not recruiting

Chest PainActive, not recruiting

Peptic Ulcer DiseaseActive, not recruiting

Calcium Metabolic DiseaseActive, not recruiting

Infectious DiseaseApproved

PneumoniaActive, not recruiting

Gastrointestinal HemorrhageApproved

Approved

Helicobacter Pylori Infectious DiseaseApproved

Approved

Lymphoid NeoplasmApproved

Approved

Gastric UlcerPreclinical

Active, not recruiting

Bacterial DiseaseApproved

Active, not recruiting

Chest PainPreclinical

Active, not recruiting

Peptic Ulcer DiseasePreclinical

Active, not recruiting

Calcium Metabolic DiseasePreclinical

Active, not recruiting

Infectious DiseaseApproved

Approved

PneumoniaPreclinical

Active, not recruiting

Showing 10 of 19 indications

Competition

Competitive Landscape

155 competitors in Pneumonia

#DrugCompanyPhaseTrials

Aciphex

Akero Therapeutics

Approved

1 2

Innohep

Jazz Pharmaceuticals

Preclinical

1 3

Plaquenil

Jazz Pharmaceuticals

Preclinical

1 4

Jakafi

Incyte

Preclinical

1 5

Primaquine

Sanofi

Preclinical

1 6

Avlosulfon

AAlmirall, S.A.

Preclinical

4 7

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 8

Zantac 150

CChattem

Preclinical

2 9

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 10

Advil

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Study completion

NCT07797478

Q2 2028

Phase 1Active, not recruiting

Advanced Solid Malignancies

NCT06899061

Q3 2028

Post-ApprovalNot yet recruiting

Percutaneous Coronary Intervention

NCT07471867

Clinical

Trials by Indication[1]

Tics9 trials

A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants

Completed·PPMV Pharmaceuticals, Inc·Phase 1·NCT06054464·28 enrolled

A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet

Completed· Roche logo

Roche·Phase 1·NCT01287091·46 enrolled

A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants

Completed· Roche logo

Roche·Phase 1·NCT03290703·63 enrolled

Show 6 more trials

Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant

Completed·—·Phase 1·NCT05899829·42 enrolled

Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers

Completed·LLomond Therapeutics Holdings, Inc.·Phase 1·NCT06787131·104 enrolled

Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat

Completed·AAkebia Therapeutics·Phase 1·NCT03789032·20 enrolled

A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants

Recruiting· Roche logo

Roche·Phase 1·NCT07329972·48 enrolled

A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755

Recruiting·VVoronoi, Inc·Phase 1·NCT07141381·24 enrolled

A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT00999128·50 enrolled

Gastroesophageal Reflux Disease5 trials

Sleep Disorders and Gastroesophageal Reflux Disease (GERD)

Completed·UUniversity of North Carolina·Phase 4·NCT00287391·20 enrolled

A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00787891·127 enrolled

Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)

Completed·UUniversity of Kansas·Phase 2·NCT00222170·24 enrolled

Show 2 more trials

Narrow-band Imaging, Autofluorescence Imaging and Gastroesophageal Reflux Disease

Unknown status·—··NCT01504971·95 enrolled

A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

Completed· Eisai logo

Eisai·Phase 3·NCT02135107·517 enrolled

Interaction4 trials

HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

Completed·HHutchmed·Phase 1·NCT05602597·59 enrolled

A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib

Completed· Roche logo

Roche·Phase 1·NCT01772290·92 enrolled

Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects

Completed·BBoston Pharmaceuticals·Phase 1·NCT03464058·28 enrolled

Show 1 more trial

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

Completed·KKadmon Corporation, LLC·Phase 1·NCT03530995·73 enrolled

Duodenal Ulcer3 trials

Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients

Completed·LLivzon Pharmaceutical Group Inc.·Phase 2/3·NCT02847455·408 enrolled

A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.

Unknown status·SSihuan Pharmaceutical Holdings Group Ltd.·Phase 3·NCT04215653·448 enrolled

Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

Completed· Eisai logo

Eisai·Phase 2/3·NCT01398410·405 enrolled

ART3 trials

Study of BIIB091 Formulations in Healthy Participants

Completed· Biogen logo

Biogen·Phase 1·NCT04564612·59 enrolled

A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants

Completed· Roche logo

Roche·Phase 1·NCT01277718·20 enrolled

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

Completed·AAlumis Inc·Phase 1·NCT05330858·14 enrolled

49 more indications

First-line Treatment3 trials

Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05419674·393 enrolled

Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT07122024·414 enrolled

Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment

Unknown status·SShanghai Zhongshan Hospital·Phase 4·NCT04667299·270 enrolled

Drug Interactions2 trials

A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants

Completed· Eisai logo

Eisai·Phase 1·NCT04565574·42 enrolled

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

Completed· Biogen logo

Biogen·Phase 1·NCT06264440·18 enrolled

GERD2 trials

Maintenance Intermittent Therapy for Symptomatic GERD Patients

Completed· Eisai logo

Eisai·Phase 2·NCT00165841·200 enrolled

Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD

Completed·VVA Greater Los Angeles Healthcare System·Phase 4·NCT00304421·23 enrolled

Adult2 trials

A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.

Completed· Pfizer logo

Pfizer·Phase 1·NCT06105983·40 enrolled

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT06417229·102 enrolled

MPA2 trials

A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole

Completed·AAddpharma Inc.·Phase 1·NCT04494243·40 enrolled

A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole

Completed·AAddpharma Inc.·Phase 1·NCT04622358·43 enrolled

GastroIntestinal Bleeding2 trials

Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents

Not yet recruiting·—·Phase 1·NCT07339956·60 enrolled

Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.

Completed·IIl-Yang Pharm. Co., Ltd.·Phase 4·NCT02638584·176 enrolled

Esophagitis2 trials

Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole

Withdrawn·XXijing Hospital of Digestive Diseases·Phase 4·NCT02986685

An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01008696·217 enrolled

Oral2 trials

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04489797·35 enrolled

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05630677·21 enrolled

Gastroesophageal Reflux2 trials

Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol

Terminated· Johnson & Johnson logo

Johnson & Johnson··NCT00511966·1,049 enrolled

Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects

Completed·NNantes University Hospital·Phase 2·NCT01136317

Age2 trials

Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication

Unknown status·—·N/A·NCT03802318·530 enrolled

Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food

Completed· Pfizer logo

Pfizer·Phase 1·NCT02097329·27 enrolled

Asthma2 trials

Improvement in Bronchial Asthma in Patients With Extraesophageal Reflux After Acid Suppression

Completed·PPonce Gastroenterology Research·N/A·NCT00234117·40 enrolled

Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.

Completed·AAssociated Scientists to Help Minimize Allergies·Phase 3·NCT00214552·80 enrolled

Prevention2 trials

ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA

Completed·—·Phase 3·NCT01408186·264 enrolled

Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection

Completed·TThe Catholic University of Korea·Phase 4·NCT00844675·120 enrolled

Helicobacter Pylori Eradication2 trials

Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT04697186·524 enrolled

Helicobacter Pylori Eradication and Follow-up

Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT05061732·4,447 enrolled

Helicobacter Pylori Infection1 trial

Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05718609·855 enrolled

NERD1 trial

Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD

Withdrawn·IInje University·Phase 3·NCT01391715

Absorption1 trial

Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04944771·48 enrolled

BRAF V600 Mutation1 trial

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

Completed· GSK logo

GSK·Phase 1·NCT01954043·23 enrolled

Randomized Controlled Trial1 trial

Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients

Completed·HHospital Authority, Hong Kong·N/A·NCT00517114·200 enrolled

Upper Gastrointestinal Bleeding1 trial

Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding

Unknown status·KKaohsiung Medical University Chung-Ho Memorial Hospital·Phase 4·NCT00861640·200 enrolled

Helicobacter Pylori1 trial

The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar

Completed·KKirby Institute·Phase 4·NCT04132479·313 enrolled

TED1 trial

A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers

Completed·PPopulation Health Research Institute·Phase 4·NCT04157881·46 enrolled

Peptic ulcer1 trial

Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers

Terminated·TThe Catholic University of Korea·Phase 4·NCT00838682·106 enrolled

Genetic Polymorphism1 trial

CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing

Completed·NNational Taiwan University Hospital·Phase 4·NCT00354757·200 enrolled

Antibiotic1 trial

Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients

Unknown status·SShanghai Zhongshan Hospital·Phase 4·NCT05023577·504 enrolled

Gastric Acid1 trial

A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03979248·21 enrolled

Aspirin1 trial

Rabeprazole Protection of Aspirin Induced Gastric Damage.

Completed·TTemple University·Phase 4·NCT00220857·30 enrolled

Pediatric1 trial

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

Completed· Takeda logo

Takeda·Phase 1·NCT05918822·32 enrolled

Heartburn1 trial

Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00553449·48 enrolled

Efficacy and Safety1 trial

Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT05014334·300 enrolled

Function1 trial

Effects of YF476 and Rabeprazole on Gastric Function

Completed·TTrio Medicines Ltd.·Phase 1·NCT01699113·32 enrolled

Female1 trial

Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants

Completed· Roche logo

Roche·Phase 1·NCT03237741·18 enrolled

Non-erosive Reflux Disease (NERD)1 trial

A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00236392·422 enrolled

Peptic Ulcer Disease1 trial

Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases

Completed·JJiangxi University of Traditional Chinese Medicine·N/A·NCT03320538·360 enrolled

Gastric1 trial

A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02475161·16 enrolled

Injury1 trial

A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury

Completed·—·Phase 3·NCT01140828·112 enrolled

Reflux1 trial

A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes

Completed·NNational Taiwan University Hospital·N/A·NCT00681005·178 enrolled

Chest pain1 trial

A Study of the Use of High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study

Unknown status·HHospital Authority, Hong Kong·N/A·NCT00517270·200 enrolled

Treatment1 trial

PPI-amoxicillin for H. Pylori Treatment

Unknown status·SShanghai Zhongshan Hospital·Phase 4·NCT05014685·732 enrolled

Dyspepsia1 trial

A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)

Completed· Eisai logo

Eisai·Phase 2·NCT01089543·338 enrolled

Pneumonia1 trial

Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02555852·4,238,504 enrolled

Amyotrophic Lateral Sclerosis1 trial

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

Completed· Roche logo

Roche·Phase 1·NCT02655614·54 enrolled

AIN1 trial

Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers

Completed·UUniversity of California, San Francisco·N/A·NCT01237353·6 enrolled

Gastro-oesophageal Reflux Disease1 trial

A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00464308·1,392 enrolled

Percutaneous Coronary Intervention1 trial

Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention

Not yet recruiting·YYonsei University·Phase 4·NCT07471867·100 enrolled

Phase 21 trial

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

Completed· Pfizer logo

Pfizer·Phase 1·NCT03130556·24 enrolled

Methotrexate1 trial

Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects

Completed· Roche logo

Roche·Phase 1·NCT02699710·50 enrolled

Advanced Solid Malignancies1 trial

A Modular Phase I, Open-label Study to Assess the Safety, Pharmacokinetics, and Drug Interaction Potential and Relative Bioavailability of Saruparib in Patients With Advanced Solid Malignancies

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT06899061·41 enrolled

Solid Tumor1 trial

A Phase 1/2 Study of BMS-986408 Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT05407675·68 enrolled

Unspecified14 trials

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

Completed· Pfizer logo

Pfizer·Phase 1·NCT05446142·18 enrolled

Tetracycline Versus Doxycycline for HP Rescue Therapy

Unknown status·SShanghai Zhongshan Hospital·Phase 4·NCT05018923·242 enrolled

HMPL-523 Food Effect and Proton Pump Inhibitor Study

Completed·HHutchmed·Phase 1·NCT05571787·26 enrolled

Show 11 more trials

PPI And Food Effect Study For PF-06463922 In Healthy Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT02569554·27 enrolled

Study of E3810 for Healthy Japanese Male (Under Fasting Condition)

Completed· Eisai logo

Eisai·Phase 1·NCT01085695·16 enrolled

Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib

Completed· Pfizer logo

Pfizer·Phase 1·NCT03220191·12 enrolled

A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)

Completed· Eisai logo

Eisai·Phase 1·NCT01085708·16 enrolled

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

Completed·HHutchmed·Phase 1·NCT05930119·24 enrolled

Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers

Completed·LLomond Therapeutics Holdings, Inc.·Phase 1·NCT06399315·112 enrolled

Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04211545·24 enrolled

An Open-Label, Randomized, Four-Period, Six-Sequence Phase I Study to Evaluate the Effect of Food and Proton Pump Inhibitor Rabeprazole on the Pharmacokinetics of HMPL-760 Capsules in Healthy Participants

Completed·HHutchmed·Phase 1·NCT07643272·24 enrolled

A Phase 1, Open-label, Randomized, Four-way Crossover Study to Assess the Relative Bioavailability of Two Phase 3 LY4100511 (DC-853) Tablet Formulations Compared With the Phase 2 LY4100511(DC-853) Tablet Formulation, With and Without a Proton Pump Inhibitor in Healthy Participants

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT06916143·1 enrolled

A Phase 1, Open Label, Fixed Sequence Study to Investigate the Effect of Rabeprazole on the Pharmacokinetics of PF-08049820 in Healthy Chinese Adult Participants.

Completed· Pfizer logo

Pfizer·Phase 1·NCT07284173·18 enrolled

A Phase I Study to Evaluate the Safety and Pharmacokinetics of RO7890597 Following Single and Multiple Ascending Doses, and the Effects of Food, Proton-Pump Inhibition, And CYP3A Inhibition in Healthy Adult Volunteers

Recruiting· Roche logo

Roche·Phase 1·NCT07797478·139 enrolled

Regulatory

FDA Approval Timeline[5]

Aug 19, 1999

ACIPHEX

NDA NDA020973

Feb 16, 2000

ACIPHEX

NDA NDA020973

Feb 16, 2000

ACIPHEX

NDA NDA020973

Feb 28, 2000

ACIPHEX

NDA NDA020973

May 8, 2000

ACIPHEX

NDA NDA020973

Sep 20, 2000

ACIPHEX

NDA NDA020973

Dec 15, 2000

ACIPHEX

NDA NDA020973

Aug 15, 2001

ACIPHEX

NDA NDA020973

Oct 2, 2001

ACIPHEX

NDA NDA020973

Oct 2, 2001

ACIPHEX

NDA NDA020973

Feb 12, 2002

ACIPHEX

NDA NDA020973

May 29, 2002

ACIPHEX

NDA NDA020973

May 29, 2002

ACIPHEX

NDA NDA020973

Sep 23, 2002

ACIPHEX

NDA NDA020973

Sep 30, 2002

ACIPHEX

NDA NDA020973

Nov 8, 2002

ACIPHEX

NDA NDA020973

Aug 1, 2003

ACIPHEX

NDA NDA020973

Jun 3, 2005

ACIPHEX

NDA NDA020973

Jun 30, 2008

ACIPHEX

NDA NDA020973

Sep 3, 2010

ACIPHEX

NDA NDA020973

May 20, 2011

ACIPHEX

NDA NDA020973

May 8, 2012

ACIPHEX

NDA NDA020973

Oct 5, 2012

ACIPHEX

NDA NDA020973

Mar 26, 2013

ACIPHEX SPRINKLE

NDA NDA204736

Apr 19, 2013

ACIPHEX

NDA NDA020973

Oct 15, 2014

ACIPHEX

NDA NDA020973

Dec 19, 2014

ACIPHEX

NDA NDA020973

Apr 4, 2016

ACIPHEX

NDA NDA020973

Oct 24, 2016

ACIPHEX

NDA NDA020973

Jan 9, 2018

ACIPHEX

NDA NDA020973

Jun 7, 2018

ACIPHEX

NDA NDA020973

Nov 27, 2020

ACIPHEX

NDA NDA020973

Mar 4, 2022

ACIPHEX

NDA NDA020973

Jul 18, 2023

ACIPHEX

NDA NDA020973

Sources

References

[1]
ClinicalTrials.gov — 100 trial records for rabeprazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Aciphex drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — rabeprazole compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for rabeprazole. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020973). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Akero Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Potassium-Transporting Atpase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Akero Therapeutics

Aciphex

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q3 2028

Trials by Indication[1]

Tics9 trials

Gastroesophageal Reflux Disease5 trials

Interaction4 trials

Duodenal Ulcer3 trials

ART3 trials

First-line Treatment3 trials

Drug Interactions2 trials

GERD2 trials

Adult2 trials

MPA2 trials

GastroIntestinal Bleeding2 trials

Esophagitis2 trials

Oral2 trials

Gastroesophageal Reflux2 trials

Age2 trials

Asthma2 trials

Prevention2 trials

Helicobacter Pylori Eradication2 trials

Helicobacter Pylori Infection1 trial

NERD1 trial

Absorption1 trial

BRAF V600 Mutation1 trial

Randomized Controlled Trial1 trial

Upper Gastrointestinal Bleeding1 trial

Helicobacter Pylori1 trial

TED1 trial

Peptic ulcer1 trial

Genetic Polymorphism1 trial

Antibiotic1 trial

Gastric Acid1 trial

Aspirin1 trial

Pediatric1 trial

Heartburn1 trial

Efficacy and Safety1 trial

Function1 trial

Female1 trial

Non-erosive Reflux Disease (NERD)1 trial

Peptic Ulcer Disease1 trial

Gastric1 trial

Injury1 trial

Reflux1 trial

Chest pain1 trial

Treatment1 trial

Dyspepsia1 trial

Pneumonia1 trial

Amyotrophic Lateral Sclerosis1 trial

AIN1 trial

Gastro-oesophageal Reflux Disease1 trial

Percutaneous Coronary Intervention1 trial

Phase 21 trial

Methotrexate1 trial

Advanced Solid Malignancies1 trial

Solid Tumor1 trial

Unspecified14 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News